PRIMARY BREAST CANCER THERAPY GROUP - N S A B P

原发性乳腺癌治疗组 - N SA B P

• 批准号: 3556433
• 负责人: DAVID PLOTKIN
• 金额: $ 6.95万
• 依托单位: MEMORIAL CANCER RES FDN OF SOU CALIF
• 依托单位国家: 美国
• 财政年份: 1980
• 资助国家: 美国
• 起止时间: 1980-03-01 至 1987-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3556433
• 关键词: Corynebacterium; antineoplastic antibiotics; breast neoplasms; breast surgery; combination cancer therapy; combination chemotherapy; cooperative study; doxorubicin; estrogen inhibitor; estrogens; fluorouracil; human subject; human therapy evaluation; longitudinal human study; methotrexate; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; rectum neoplasms; tamoxifen

Memorial Cancer Research Foundation of Southern California (MCRF) intends to continue to contribute data derived from records of patients entered into the National Surgical Adjuvant Breast Project (NSABP) protocols B-05, B-06, B-07, B-08, B-09, B-10. This activity began in 1973 and has steadily grown ever since particularly through 2 previous grant periods (1976-1979) (1979-1982). The total contribution of patients to NSABP protocols since MCRFSC's entry into the group is second only to NASABP headquarters at the University of Pittsburgh and its associated western Pennsylvania network. For the last major adjuvant study completed, B-09, MCRFSC's numerical contribution was highest of all of the over 70 institutions participating in the USA and Canada. All NSABP studies are devoted to further our understanding of the roles of surgery, radioation therapy, chemotherapy, hormonal manipulation and/or immunotherapy in the management of primary breast cancer. The information derived from past studies are landmarks of achievement in this regard. There are four new protocols, two of which specifically aim to clarify the possible benefit of adriamycin added to L-PAM (P) + 5-Fluorouracil (F) in stage II estrogen receptor negative (ER-) patients (B-11) or to PF + Tamoxifen in stage II estrogen receptor positive (ER+) patients (B-12). The other two protocols reflect NSABP embarking for the first time on adjuvant trials in stage I disease, i.e. Tamoxifen versus a placebo in ER+ patients (B-13), sequential Methotrexate with Citrovorum Factor Rescue and 5-FU versus no treatment in ER- patients (B-14). The principal investigator is co-chairman of B-13 and B-14 monitoring committee and a member of the monitoring committee of B-11 and B-12. MCRFSC research productivity is fundamentally tied to the function of Oncology Network of Southern California (ONSC), a group of private practice medical oncologists scattered over Southern California who are interested in this type of activity. By the continued, wherever possible, expanded participation of this type of research activity, further improvement in the duration and quality of life of the greater than 100,000 women affected by breast cancer yearly will be achieved.

南加州纪念癌症研究基金会 (MCRF) 打算 继续提供从输入的患者记录中获得的数据 纳入国家乳腺辅助手术项目 (NSABP) 方案 B-05， B-06、B-07、B-08、B-09、B-10。 这项活动自1973年开始，至今已稳步开展 此后一直在增长，特别是通过之前的两个资助期（1976-1979） （1979-1982）。 自此以来患者对 NSABP 方案的总贡献 MCRFSC 的加入仅次于 NASABP 总部 匹兹堡大学及其相关的宾夕法尼亚州西部网络。 对于最后完成的主要佐剂研究，B-09，MCRFSC 的数值 70 多家参与机构中贡献最高 在美国和加拿大。 所有 NSABP 研究都致力于进一步推进我们的研究 了解手术、放射治疗、化疗的作用， 激素控制和/或免疫疗法在原发性骨髓瘤的治疗中的应用 乳腺癌。 从过去的研究中获得的信息是里程碑 在这方面取得的成就。 有四个新协议，其中两个 特别旨在澄清添加阿霉素的可能益处 L-PAM (P) + 5-氟尿嘧啶 (F) II 期雌激素受体阴性 (ER-) 患者 (B-11) 或 PF + 他莫昔芬 II 期雌激素受体阳性 (ER+) 患者 (B-12)。 另外两个协议反映了 NSABP 的启动 首次对 I 期疾病进行辅助试验，即他莫昔芬 与 ER+ 患者 (B-13) 中的安慰剂相比，序贯甲氨蝶呤联合 Citrovorum Factor Rescue 和 5-FU 对比 ER 患者不治疗 （B-14）。 首席研究员是 B-13 和 B-14 的联合主席 监督委员会以及 B-11 和 B-11 监督委员会成员 B-12。 MCRFSC 的研究生产力从根本上与职能相关 南加州肿瘤网络 (ONSC) 是一个私营组织 分布在南加州的执业肿瘤科医生 对此类活动感兴趣。 通过继续，只要有可能， 扩大此类研究活动的参与，进一步 改善超过 100,000 人的生活持续时间和质量 每年受乳腺癌影响的妇女人数将实现。